[작성자:] Ashley Zhu
-
Rare Disease Day 2026: Messages That Bring Us Together
Rare Disease Day is a moment to recognize the people behind every diagnosis — patients, families, clinicians, and teams who continue searching for answers even when cases are complex. This year, healthcare professionals and partners from around the world shared short messages of encouragement for the rare disease community. Each message reflects compassion, resilience, and…
-
Introducing Family Insight: A Family-Based Genomic Solution for Reproductive Challenges
1. The Unanswered Questions in High-Risk Reproductive Cases Recurrent pregnancy loss, stillbirth, early infant loss, and other unexplained reproductive outcomes remain some of the most challenging situations in reproductive medicine. Even with advances in genetic testing, many families never receive a clear explanation for why a pregnancy failed or why a child was lost. Results…
-
Family Testing: When and Why Is It Necessary?
Why family studies matter after Exome or Genome sequencing 1. From “a variant” to “a diagnosis” Exome and genome sequencing can identify thousands of genetic variants in a single test. However, once results are returned, clinicians and families often face the same fundamental question: “Is this variant truly responsible for my child’s symptoms?” Answering this…
-
3billion Participates in ESHG 2025 in Milan
3billion participated in the European Society of Human Genetics (ESHG) 2025, held in Milan, Italy, from May 24th to 26th. The event drew nearly 200 genetics and physicians from across Europe and around the world to our booth, creating valuable opportunities for in-depth discussions about rare disease diagnostics and genetic testing solutions. In addition to…
-
Virtual Panel Discussion: Practical Insights on Handling VUS-Europe
From Ambiguity to Action: Practical Insights on Handling VUS Understanding genetic variations and their implications is a cornerstone of advancing precision medicine. Yet, Variants of Uncertain Significance (VUS) remain a challenging gray area for clinicians and geneticists. How can we translate ambiguity into actionable insights for better patient care? To address these pressing questions, 3billion,…
-
Virtual Panel Discussion: Practical Insights on Handling VUS-Asia
From Ambiguity to Action: Practical Insights on Handling VUS Understanding genetic variations and their implications is a cornerstone of advancing precision medicine. Yet, Variants of Uncertain Significance (VUS) remain a challenging gray area for clinicians and geneticists. How can we translate ambiguity into actionable insights for better patient care? To address these pressing questions, 3billion,…
-
Will the test not proceed if the sample has not been paid for?
For patient payments, the test will not proceed if payment is not received.
-
What is 3B-VARIANT?
This test is a Sanger test to determine if a genetic mutation found in a patient is also present in family members. Unlike WES or WGS tests, this test targets the specific region of variation found in the patient. It can also be used to identify the variant that causes the condition in parents and…
-
My test is still pending. Is there a specific reason?
It could be incomplete documentation, pending payment, or QC failures etc.If there’s an issue with any of these, a sales representative will contact you to let you know.
-
Can I add the ‘sharer list’ with patient’s email account?
It is not possible to enter patient information for sharing. Due to medical law, patients’ test results must be communicated through their healthcare provider, not through 3billion. If you request to share, you will need to sign up for the 3billion portal with that account, which the patient will not be able to do due…